These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 36318154)

  • 1. Conformationally Defined Rexinoids for the Prevention of Inflammation and Nonmelanoma Skin Cancers.
    Atigadda VR; Kashyap MP; Yang Z; Chattopadhyay D; Melo N; Sinha R; Belyaeva OV; Chou CF; Chang PL; Kedishvili NY; Grubbs CJ; Renfrow MB; Muccio DD; Elmets CA; Athar M
    J Med Chem; 2022 Nov; 65(21):14409-14423. PubMed ID: 36318154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The "Phantom Effect" of the Rexinoid LG100754: structural and functional insights.
    Sato Y; Ramalanjaona N; Huet T; Potier N; Osz J; Antony P; Peluso-Iltis C; Poussin-Courmontagne P; Ennifar E; Mély Y; Dejaegere A; Moras D; Rochel N
    PLoS One; 2010 Nov; 5(11):e15119. PubMed ID: 21152046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Next-generation retinoid X receptor agonists increase ATRA signaling in organotypic epithelium cultures and have distinct effects on receptor dynamics.
    Melo N; Belyaeva OV; Berger WK; Halasz L; Yu J; Pilli N; Yang Z; Klyuyeva AV; Elmets CA; Atigadda V; Muccio DD; Kane MA; Nagy L; Kedishvili NY; Renfrow MB
    J Biol Chem; 2023 Jan; 299(1):102746. PubMed ID: 36436565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining the communication between agonist and coactivator binding in the retinoid X receptor α ligand binding domain.
    Boerma LJ; Xia G; Qui C; Cox BD; Chalmers MJ; Smith CD; Lobo-Ruppert S; Griffin PR; Muccio DD; Renfrow MB
    J Biol Chem; 2014 Jan; 289(2):814-26. PubMed ID: 24187139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The retinoid X receptor has a critical role in synthetic rexinoid-induced increase in cellular all-trans-retinoic acid.
    Belyaeva OV; Klyuyeva AV; Vyas A; Berger WK; Halasz L; Yu J; Atigadda VR; Slay A; Goggans KR; Renfrow MB; Kane MA; Nagy L; Kedishvili NY
    PLoS One; 2024; 19(4):e0301447. PubMed ID: 38557762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Isochroman Analog of CD3254 and Allyl-, Isochroman-Analogs of NEt-TMN Prove to Be More Potent Retinoid-X-Receptor (RXR) Selective Agonists Than Bexarotene.
    Jurutka PW; di Martino O; Reshi S; Mallick S; Sausedo MA; Moen GA; Lee IJ; Ivan DJ; Krall TD; Peoples SJ; Perez A; Tromba L; Le A; Khadka I; Petros R; Savage BM; Salama E; Salama J; Ziller JW; Noh Y; Lee MY; Liu W; Welch JS; Marshall PA; Wagner CE
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555852
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Conformationally Defined Rexinoids and Their Efficacy in the Prevention of Mammary Cancers.
    Atigadda VR; Xia G; Deshpande A; Wu L; Kedishvili N; Smith CD; Krontiras H; Bland KI; Grubbs CJ; Brouillette WJ; Muccio DD
    J Med Chem; 2015 Oct; 58(19):7763-74. PubMed ID: 26331194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Methyl-substituted conformationally constrained rexinoid agonists for the retinoid X receptors demonstrate improved efficacy for cancer therapy and prevention.
    Desphande A; Xia G; Boerma LJ; Vines KK; Atigadda VR; Lobo-Ruppert S; Grubbs CJ; Moeinpour FL; Smith CD; Christov K; Brouillette WJ; Muccio DD
    Bioorg Med Chem; 2014 Jan; 22(1):178-85. PubMed ID: 24359708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rexinoids modulate steroid and xenobiotic receptor activity by increasing its protein turnover in a calpain-dependent manner.
    Pettersson F; Hanna N; Lagodich M; Dupéré-Richer D; Couture MC; Choi C; Miller WH
    J Biol Chem; 2008 Aug; 283(32):21945-52. PubMed ID: 18544536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methods to Generate an Array of Novel Rexinoids by SAR on a Potent Retinoid X Receptor Agonist: A Case Study with NEt-TMN.
    Wagner CE; Jurutka PW
    Methods Mol Biol; 2019; 2019():109-121. PubMed ID: 31359392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods to Assess Activity and Potency of Rexinoids Using Rapid Luciferase-Based Assays: A Case Study with NEt-TMN.
    Jurutka PW; Wagner CE
    Methods Mol Biol; 2019; 2019():95-108. PubMed ID: 31359391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Competitive Binding Assay with an Umbelliferone-Based Fluorescent Rexinoid for Retinoid X Receptor Ligand Screening.
    Yamada S; Kawasaki M; Fujihara M; Watanabe M; Takamura Y; Takioku M; Nishioka H; Takeuchi Y; Makishima M; Motoyama T; Ito S; Tokiwa H; Nakano S; Kakuta H
    J Med Chem; 2019 Oct; 62(19):8809-8818. PubMed ID: 31483660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of Bexarotene Analogs for Treating Cutaneous T-Cell Lymphomas.
    Warda A; Staniszewski LJP; Sabir Z; Livingston S; Sausedo M; Reshi S; Ron E; Applegate MT; Haddad D; Khamisi M; Marshall PA; Wagner CE; Jurutka PW
    Cells; 2023 Nov; 12(21):. PubMed ID: 37947652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rexinoids isolated from Sophora tonkinensis with a gene expression profile distinct from the synthetic rexinoid bexarotene.
    Inoue M; Tanabe H; Nakashima K; Ishida Y; Kotani H
    J Nat Prod; 2014 Jul; 77(7):1670-7. PubMed ID: 24959987
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox.
    Gorgun G; Foss F
    Blood; 2002 Aug; 100(4):1399-403. PubMed ID: 12149223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced retinoid signaling in the skin after systemic retinoid-X receptor ligand treatment in mice with potential relevance for skin disorders.
    Mihály J; Gericke J; Aydemir G; Weiss K; Carlsen H; Blomhoff R; Garcia J; Rühl R
    Dermatology; 2012; 225(4):304-11. PubMed ID: 23296452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of RXR function through ligand design.
    Pérez E; Bourguet W; Gronemeyer H; de Lera AR
    Biochim Biophys Acta; 2012 Jan; 1821(1):57-69. PubMed ID: 21515403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induced differentiation of acute myeloid leukemia cells by activation of retinoid X and liver X receptors.
    Sanchez PV; Glantz ST; Scotland S; Kasner MT; Carroll M
    Leukemia; 2014 Apr; 28(4):749-60. PubMed ID: 23823656
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.
    Moerland JA; Zhang D; Reich LA; Carapellucci S; Lockwood B; Leal AS; Krieger-Burke T; Aleiwi B; Ellsworth E; Liby KT
    Sci Rep; 2020 Dec; 10(1):22244. PubMed ID: 33335263
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Testing Novel Pyrimidinyl Rexinoids: A New Paradigm for Evaluating Rexinoids for Cancer Prevention.
    Zhang D; Leal AS; Carapellucci S; Shahani PH; Bhogal JS; Ibrahim S; Raban S; Jurutka PW; Marshall PA; Sporn MB; Wagner CE; Liby KT
    Cancer Prev Res (Phila); 2019 Apr; 12(4):211-224. PubMed ID: 30760500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.